Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

Affiliation auteurs!!!! Error affiliation !!!!
TitreResults of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.
Type de publicationJournal Article
Year of Publication2018
AuteursDuffaud F, Blay J-Y, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Thyss A, Isambert N, Delaye J, Carvalho NDe Sousa, Schiffler C, Bouvier C, Vidal V, Chabaud S
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.11504